Genelux Q2 Loss Widens to $9.5M; Phase 3 Ovarian Cancer Data Due 2H26
GNLX is trading near its 52-week low of $2.29 (15% above the low).
Summary
Genelux reported Q2 results with a net loss of $9.5 million, wider than expected, driven by higher Phase 3 trial costs and R&D expenses. Cash and equivalents totaled $18.7 million as of June 30, 2026, expected to fund operations into Q1 2027. The company reiterated that topline data from the Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer is anticipated in the second half of 2026. Additional dose-escalation updates from systemic lung cancer programs are expected in 2026. The going concern warning remains in place, consistent with the 10-Q filed earlier today.
At the time of this announcement, GNLX was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.9M. The 52-week trading range was $2.29 to $8.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.